Answers are grounded in this paper and cite their sources.
A 4-year-old boy presented with a 6-week history of a skin lesion on his left mandibular angle. The lesion initially appeared as a small nodule that rapidly increased in size. Pain, itch, and other subjective complaints were denied. Topical therapies with steroids, antibiotics and calcineurin inhibitors did not improve the lesion, which instead showed further size progression. Clinical examination revealed a brown-red, relatively firm plaque, measuring approximately 2.5 cm in diameter with isolated telangiectasia on the left mandibular angle (Figure 1). Blood testing showed no abnormalities for red and white blood cells or platelets. Liver and kidney functions were normal and electrolyte balance presented standard values. A 4-mm skin biopsy and histological reprocessing was performed (Figure 2). Histological findings of the skin biopsy showed a narrow grenz zone between epidermis and dermis as well as a dense and diffuse B-cell-rich pseudolymphomatous infiltrate with numerous plasma cells throughout the entire dermis. Occasional multinucleated histiocytic giant cells were also observed. Immunohistochemical staining showed significant positivity for CD-20 (Figure 3a) and CD-3 (Figure 3b) and a mixed positivity for CD-68 and CD-30. The typing of light chains, CD-4, CD-8 and Ki-67 was not possible due to the limited size of the sample. In synopsis of the findings, a diagnosis of B-cell pseudolymphoma was made. No further treatments were performed and a complete remission was observed 8 weeks after biopsy, with only a small scar at the biopsy site remaining (Figure 4). Six years later, the patient is symptom free. The initial clinical presentation, with rapid growth of a hemispherical nodule located on the face, first suggested juvenile xanthogranuloma. Differential diagnostic considerations comprised cutaneous B-cell lymphoma, pseudolymphoma including lymphadenosis cutis benigna, and Langerhans cell histiocytosis. Histological examinations were key to achieve a final diagnosis. Cutaneous pseudolymphomas are characterized by benign skin lesions that cannot be differentiated clinically and histologically from malignant cutaneous lymphomas. Pseudolymphomas can develop idiopathically as well as in response to exogenous triggers. As cutaneous pseudolymphoma occurs mainly in adults (>90% of patients are aged over 34), limited epidemiological and clinical data is available in children.1 Cases of cutaneous pseudolymphoma in response to vaccines, injections, insect bites and trauma in children have been described, whereas tattoos and piercings play a role in the development of pseudolymphoma in adults.1 In the present case, an insect bite is believed to be a possible trigger despite a corresponding history of an insect bite being explicitly denied by the patient's family. Cutaneous pseudolymphomas usually present clinically as light red to brown macules, papules, nodules, or infiltrated plaques. Less commonly they can also present as erythema. The skin lesions often persist for weeks to years, showing spontaneous regression and healing, as well as a tendency for recurrences.2 Pseudolymphomas can be differentiated by the immunophenotype of the infiltrating cells. For example, lymphadenosis cutis benigna is a B-cell cutaneous pseudolymphoma that is caused by Borrelia infection. Serological testing for Borrelia was therefore conducted in the present case, for which results were negative. In addition to B-cell pseudolymphomas, pseudolymphomas with a T-cell immunophenotype, like actinic reticuloid and lymphomatoid contact dermatitis, and with a mixed immunophenotype, like lymphomatoid drug reaction, can be distinguished.3 Because pseudolymphomas can have clinical presentations very similar to those of cutaneous lymphomas, a correct diagnosis can often only be made with skin biopsies and, if necessary, molecular genetic testing. The histology typically shows a lymphocytic infiltrate with cell polymorphism as well as epidermal and vascular involvement as described in the present case.3 The clinical course of cutaneous pseudolymphoma can be highly variable. While some undergo spontaneous regression, others persist for months or even years. Different therapies are required depending on the aetiology of the disease. While drug-associated pseudolymphomas are treated with topical or intralesional steroids, Borrelia-associated pseudolymphoma is treated with oral doxycycline.2 Intralesional steroids, topical calcineurin inhibitors, lasers, and surgical procedures are therapeutic options for lymphomatoid contact dermatitis. For a case of pseudolymphomatous folliculitis (PLF), which clinically presents as an erythematous nodule, spontaneous regression has been reported. The PLF was interpreted as a delayed response to an antigen localized in either the follicle lumen or epithelium. The skin biopsy that was carried out might have led to removal of the responsible antigen, thus resulting in spontaneous regression of the skin lesion after approximately 4 weeks.4 Spontaneous remissions are found with varying frequency depending on the underlying aetiology for pseudolymphoma. While no remission has been described for actinic reticuloid because of its chronic nature, remission is frequently observed for insect bite reactions and lymphomatoid drug reactions after discontinuing the use of the offending drug.4 As there is a risk of a disease transformation to lymphoma, regular clinical follow-up and reevaluations over a period of 5 years are recommended accordingly.5 The funding information is not available. Sarah Preis, Alphina Kain and Sigird Möckel have no conflict of interest to report. Alexander Zink is member of the German Society of Dermatology and leader of the Digital Dermatology group within this society. Tilo Biedermann received grants or contracts from Celgene-BMS, Lilly, Novartis, Sanofi-Genzyme, Regeneron, Viatris, consulting fees from AbbVie, Alk-Abello, Boehringer-Ingelheim, Leo Pharma, Lilly, Novartis, Sanofi-Genzyme and payment or honoraria from Alk-Abello, Leo Pharma, Lilly, Novartis, Sanofi-Genzyme, Regeneron, participation on data/advisory board of Alk-Abelllo, Leo Pharma, Lilly, Sanofi-Genzyme, Viatris, furthermore, he was Past-President of the German Society of Dermatology. Informed consent of the participant was obtained. The patient in this manuscript have given written informed consent to the publication of their case details. The authors confirm that the data supporting the findings of this case report are available within the article. Raw data that support the findings are available from the corresponding author upon request.
No takes yet. Share an insight, caveat, or question.
Preis et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: